225
Participants
Start Date
January 31, 2005
Primary Completion Date
October 31, 2007
Study Completion Date
October 31, 2009
Thalidomide
Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
Dexamethasone
Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
DOXIL
DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
Fountain Valley
Greenbrae
La Verne
Los Angeles
Denver
New London
Boca Raton
Jacksonville
Miami
Orange City
Ormond Beach
Lawrenceville
Chicago
Indianapolis
Wichita
Baltimore
Bethesda
Minneapolis
Saint Louis Park
Columbia
Kansas City
Omaha
Englewood
Hackensack
Jersey City
Voorhees Township
Albany
Armonk
Box 302
Brooklyn
Nyack
The Bronx
Valhalla
Durham
Winston-Salem
Cleveland
Oklahoma City
Tulsa
Eugene
Pittsburgh
Wynnewood
Columbia
Easley
Sumter
Memphis
Nashville
Bedford
Dallas
Fort Worth
Fredericksburg
Houston
Burlington
Fairfax
Norfolk
Richmond
Spokane
Vancouver
Yakima
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
INDUSTRY
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY